Insider · CIK 0001754129
Justin D. Gover
director
Files at XENE (Xenon Pharmaceuticals Inc.), DSGN (Design Therapeutics, Inc.), CMPS (COMPASS Pathways plc). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | DSGN Design Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jan 5, 2026 |
| Sep 9, 2025 | DSGN Design Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Sep 10, 2025 |
| Sep 9, 2025 | DSGN Design Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +15,833 | $0.00 | $0 | 15,833 | Sep 10, 2025 |
| Jul 29, 2025 | CMPS COMPASS Pathways plc | AGrant or award Share Option (Right to Buy)derivative | +52,000 | $0.00 | $0 | 52,000 | Jul 30, 2025 |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.